Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium

Overview of attention for article published in Investigational New Drugs, November 2010

Altmetric Badge

Mentioned by

patent: 9 patents

Citations

dimensions_citation: 75 Dimensions

Readers on

mendeley: 59 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 9 patents that reference this research output.

Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Grant US-RE49353-E1

United States of America

Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Grant US-11491149-B2

United States of America

Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Grant US-11160796-B2

United States of America

Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Grant US-10849888-B2

United States of America

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity, including 5 additional patents.